Evogene Stock Price, News & Analysis

Evogene (NASDAQ: EVGN), a computational biology company focused on life-science product discovery and development, has scheduled its Q2 2025 financial results release for Tuesday, August 19, 2025. The company will host a conference call to discuss the results at 9:00 AM ET (4:00 PM Israel time).

Interested participants must register in advance through the company's dedicated conference link. A recording of the conference will be made available on Evogene's website following the event.

Evogene (NASDAQ: EVGN) has completed the previously announced sale of its ag-biologicals subsidiary Lavie Bio to ICL Group (NYSE: ICL). The transaction includes the transfer of Lavie Bio's proprietary Biology Driven Design (BDD) technology platform, microbial bank, development pipeline, commercial products, and core personnel. Additionally, Evogene has divested its MicroBoost AI Tech-Engine for Agriculture to ICL.

The deal excludes Lavie Bio's existing strategic partnerships and commercial agreements, which will continue to generate potential future revenues for Lavie Bio's shareholders. This strategic move aligns with Evogene's goal to unlock subsidiary value while strengthening ICL's position in the global ag-biologicals market.

Evogene (NASDAQ: EVGN) has completed version 1.0 of its generative AI foundation model for small molecule design, developed with Google Cloud. The model enhances ChemPass AI's capabilities by simultaneously addressing multiple complex product criteria in pharmaceutical and agricultural applications. The proprietary model achieves 90% precision in novel molecule designs, compared to 29% in traditional GPT AI models, and is built on a dataset of 38 billion molecular structures. The technology enables the creation of potent, synthesizable, and patentable molecules while ensuring strong IP portfolios. Evogene is already developing version 2.0, focusing on enhanced multi-parameter optimization for therapeutic and agricultural applications.

Evogene (NASDAQ: EVGN) reported Q1 2025 financial results with revenues of $2.4 million, down from $4.2 million in Q1 2024. The company reduced operating expenses to $5.0 million from $8.0 million year-over-year. Key developments include ICL's planned acquisition of Lavie Bio's operations for $15.25 million and MicroBoost AI for Ag for $3.5 million, expected to close in Q2 2025. Cash position stood at $9.8 million as of March 31, 2025. The company is focusing on two strategic priorities: developing ChemPass-AI tech-engine for pharmaceutical applications and generating value from subsidiaries. Notable subsidiary updates include Casterra's delivery of 250 tons of castor seeds, AgPlenus's discovery of a new fungicide mode of action, and Biomica's progress in clinical trials.

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a computational biology company focused on life-science product discovery and development, has announced it will release its Q1 2025 financial results on Wednesday, May 21, 2025. The company will host a conference call to discuss the results at 9:00 AM ET (4:00 PM Israel time) on the same day. Interested participants can register for the conference call through the company's provided link. The conference recording will be made available on Evogene's website in the following days.

Evogene (Nasdaq: EVGN) has announced a definitive agreement for ICL to acquire the majority of activities of its subsidiary, Lavie Bio , along with Evogene's MicroBoost AI for AG platform. The transaction is expected to close in Q2 2025.

The acquisition includes Lavie Bio's core team, BDD technology platform, microbial bank, data assets, development programs, and commercial products. Lavie Bio's existing partner agreements will remain with current shareholders. This deal follows ICL Planet's strategic investment and over two years of collaboration between ICL and Lavie Bio in developing bio-stimulant solutions for row crops.

Lavie Bio specializes in microbiome-based ag-biological products aimed at improving agricultural productivity and sustainability. The integration aims to accelerate the development of innovative agricultural solutions globally.

Evogene (NASDAQ: EVGN) reported its Q4 and full-year 2024 financial results, showing significant revenue growth to $8.5 million in 2024, up from $5.6 million in 2023. The increase was primarily driven by AgPlenus' Bayer collaboration and Casterra's seed sales.

The company reduced its net loss to $18.1 million in 2024 from $26.0 million in 2023, while R&D expenses decreased to $16.6 million from $20.8 million. Cash position stood at $15.3 million as of December 31, 2024, with reduced cash usage of $10.4 million in 2024.

Strategic highlights include:

• Implementation of a 30% headcount reduction plan
• Focus on ChemPass AI tech-engine for drug discovery
• Plans for subsidiary exit events
• Expansion of Casterra's castor seed business with significant delivery increases

Evogene (Nasdaq: EVGN) has announced the appointment of Nir Nimrodi as the new Chairperson of the Board, effective March 5, 2025. He succeeds Sarit Firon, who will continue serving as a board member. Nimrodi, who has been a board member since September 2022, brings over 20 years of international experience in life sciences, pharmaceutical, and biotechnology sectors.

The company's CEO, Ofer Haviv, will also join as a board member. Nimrodi has been involved with Evogene since 2020, initially as a special advisor before becoming a board member. The new chairman expressed commitment to unlocking shareholder value and leveraging the company's AI capabilities in drug discovery.

Evogene (Nasdaq: EVGN) (TASE: EVGN), a computational biology company focused on life-science product discovery and development, has announced it will release its fourth quarter 2024 financial results on Thursday, March 6, 2025.

The company will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time) on the same day. Interested parties can register for the Zoom conference call through the provided link. The conference recording will be made available on the company's website following the event.